Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation

European Journal of Endocrinology

Volumn 161, Issue 6, 2009, Pages 877-885

  McKillop, Aine M ^a   Duffy, Nicola A ^a   Lindsay, John R ^b   Green, Brian D ^c   Patterson, S ^a   O'Harte, Finbarr P M ^a   Bell, Patrick M ^d   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; PLACEBO; VILDAGLIPTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IC 50; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ANTIGENS, CD26; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; INSULIN; MALE; MIDDLE AGED; NITRILES; PHENYLALANINE; PYRROLIDINES;

EID: 72949089282     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0547     Document Type: Article

References (53)

1. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE & Dunning BE. Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001 26 983-988.
2. Uchino H, Niwa M, Shimizu T, Nishiyama K & Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycaemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocrine Journal 2000 47 639-641.
3. Carroll MF, Gutierrez A, Castro M, Tsewang D & Schade D. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2003 88 5248-5254.
4. Campbell IW. Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus. International Journal of Clinical Practice 2005 59 1218-1228.
5. Keilson L, Mather S, Walter YH, Subramanian S & McLeod JF. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2000 85 1081-1086.
6. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes & Metabolism 2006 32 113-120.
7. Hu S. Interaction of nateglinide with K(ATP) channel in β cells underlies its unique insulinotropic action. European Journal of Pharmacology 2002 442 163-171.
8. Hu S, Boettcher BR & Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003 46 M37-M43.
9. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clinical Pharmacokinetics 2004 43 97-120.
10. Mentlein R, Gallwitz B & Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993 214 829-835.
11. Holst JJ & Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology. Endocrinology and Metabolism 2004 287 E199-E206.
12. Green BD, Gault VA, O'Harte FP & Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current Pharmaceutical Design 2004 10 3651-3662.
13. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006 3 153-165.
14. Flatt PR, Bailey CJ & Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Frontiers in Bioscience 2008 13 3648-3660.
15. Mentzel S, Dijkman HBPM, Vanson JPHF, Koene RAP & Assmann KJM. Organ distribution of aminopeptidase A and dipeptidyl peptidase-IV in normal mice. Journal of Histochemistry and Cytochemistry 1996 44 445-461.
16. Ahren B & Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabolic Research 2004 36 867-876.
17. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004 53 2181-2189.
18. Green BD, Flatt PR & Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. Expert Opinion on Emerging Drugs 2006 11 525-539.
19. Green BD, Flatt PR & Bailey CJ. Dipeptidylpeptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes & Vascular Disease Research 2006 3 159-165.
20. Mentlein R. Therapeutic assessment of glucagon-like peptide 1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic agents. Expert Opinion on Investigational Drugs 2005 14 57-64.
21. Meneilly GS, Demuth HU, McIntosh CH & Pederson RA. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabetic Medicine 2000 17 346-350.
22. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G & Rotella CM. Effects of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001 24 489-494.
23. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T & Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochemical and Biophysical Research Communications 2002 298 779-784.
24. Lenhard JM, Croom DK & Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochemical and Biophysical Research Communications 2004 324 92-97.
25. McKillop AM, Duffy NA, Lindsay JR, O'Harte FPM, Bell PM & Flatt PR. Decreased dipeptidyl peptidase-IV activity and glucagonlike peptide-1(7-36) amide degradation in type 2 diabetic subjects. Diabetes Research and Clinical Practice 2008 79 79-85.
26. Feron D, Bequ-Le Corroller A, Piot JM, Frelicot C, Vialettes B & Fruitier-Arnaudin I. Significant lower VVH7-like immunoreactivity serum level in diabetic patients: evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP. Peptides 2009 30 256-261.
27. Vilsboll T, Krarup T, Deacon CF, Madsbad S & Holst JJ. Reduced postprandial concentration of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes 2001 50 609-613.
28. Mannucci E, Pala L, Ciani S, Bardini G, Prezzatini A, Sposato I, Cremasco F, Ognibene A & Rotella CM. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005 48 1168-1172.
29. Duffy N, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP & Flatt PR. Effects of antidiabetic drugs in dipeptidyl peptidase IV: nateglinide is an inhibitor of DPPIV and augments antidiabetic activity of glucagon-like peptide-1. European Journal of Pharmacology 2007 568 278-286.
30. Fujiwara K & Tsuru D. New chromogenic and fluorogenic substrates for pyrrolidonyl peptidase. Journal of Biochemistry 1978 83 1145-1149.
31. Stevens JF. Determination of glucose by an automatic analyser. Clinica Chimica Acta 1971 32 199-201.
32. Fossati P, Ponti M, Passoni G, Tarenqhi G, Melzi d'Eril GV & Prencipe L. A step forward in enzymatic measurement of creatinine. Clinical Chemistry 1994 40 130-137.
33. Burington RS. Handbook of Mathematical Tables and Formulas. New York: McGraw-Hill, 1973.
34. Brandt I, Joossens J, Chen X, Maes M-B, Scharpé S, De Meester I & Lambeir A-M. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)-amino]acetyl}- pyrrolidine-2-carbonitrile). Biochemical Pharmacology 2005 70 134-143.
35. Hazama Y, Matsuhisa M & Ohtoshi K. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Research and Clinical Practice 2006 71 251-255.
36. Herman GA, Stein PP, Thornberry NA & Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clinical Pharmacology and Therapeutics 2007 81 761-767.
37. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS & Demuth H-U. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochemical and Biophysical Research Communications 2002 291 1302-1308.
38. Lindsay JR, Duffy N, McKillop AM, Ardill J, O'Harte FP, Flatt PR & Bell PM. Inhibition of dipeptidyl peptidase IV (DPP IV) activity by oral metformin in type 2 diabetes. Diabetic Medicine 2005 22 654-657.
39. Green BD, Duffy NA, Irwin N, Gault VA, O'Harte FP & Flatt PR. Inhibition of dipeptidyl peptidase-IV (DPP IV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1). European Journal of Pharmacology 2006 547 192-199.
40. Barnett AH. Translating science into clinical practice: focus on vildagliptin in combination with metformin. Diabetes, Obesity & Metabolism 2009 11 18-26.
41. Cataland S, Crockett SE, Brown JC & Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. Journal of Clinical Endocrinology and Metabolism 1974 39 223-228.
42. Falko JM, Crockett SE, Cataland S & Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. Journal of Clinical Endocrinology and Metabolism 1975 41 260-265.
43. Drucker DJ. The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation 2007 117 24-32.
44. Baggio LL & Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007 132 2131-2157.
45. McIntosh CH, Widenmaier S & Kim SJ. Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitamins and Hormones 2009 80 409-471.
46. Irwin N & Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009 52 1724-1731.
47. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF & AndersenDK. GLP-1(9-36) amide, cleavage product ofGLP-1(7-36) amide, is a glucoregulatory peptide. Obesity 2008 16 1501-1509.
48. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK & Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009 94 1843-1852.
49. Ossum A, van Deurs U, Engstrøm T, Jensen JS & Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36) amide in an isolated rat heart. Pharmacological Research 2009 60 411-417.
50. McKillop AM, Duffy NA, Lindsay JR, Green BD, O'Harte FPM, Bell PM & Flatt PR. Insulinotropic actions of nateglinide are accompanied by inhibition of dipeptidyl peptidase-IV activity. Diabetologia 2006 49 (Suppl 1) 482.
51. Choudhury S, Hirschberg Y, Filipek R, Lasseter K & McLeod JF. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. Journal of Clinical Pharmacology 2000 40 634-640.
52. Deacon CF, Hughes TE & Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagonlike peptide 1 in the anesthetized pig. Diabetes Care 1998 47 764-767.
53. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME & Hughes TE. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl] -2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry 2003 46 2774-2789.